179089-06-6

Basic information

• Product Name: C₂₁H₁₈N₄
• CAS NO: 179089-06-6
• Molecular Weight: 326.401
• Mol File: 179089-06-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₁H₁₈N₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₁₈N₄(179089-06-6)
• EPA Substance Registry System: C₂₁H₁₈N₄(179089-06-6)

Safety Data

• Hazardous Substances Data: 179089-06-6(Hazardous Substances Data)

Upstream product

• 114772-53-1 2-Cyano-4'-methylbiphenyl 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 2042-37-7 o-cyanobromobenzene 
• 100-39-0 benzyl bromide 
• 120568-11-8 5-<4'-Methyl-1,1'-biphenyl-2-yl>-1H-tetrazole 

Downstream Products

• 1295434-61-5 Br^(1-)*C₄₇H₄₃N₆⁽¹⁺⁾ 
• 1084950-09-3 N-(benzyl)-5-[4'-(bromomethyl)-biphenyl-2-yl]tetrazole 

Relevant articles and documents

An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT1 Angiotensin II receptor antagonist: Reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies

A new 1,5 disubstituted imidazole AT1 Angiotensin II (AII) receptor antagonist related to losartan with reversion of butyl and hydroxymethyl groups at the 2-, 5-positions of the imidazole ring was synthesized and evaluated for its antagonist activity (V8). In vitro results indicated that the reorientation of butyl and hydroxymethyl groups on the imidazole template of losartan retained high binding affinity to the AT 1 receptor concluding that the spacing of the substituents at the 2,5- positions is of primary importance. The docking studies are confirmed by binding assay results which clearly show a comparable binding score of the designed compound V8 with that of the prototype losartan. An efficient, regioselective and cost effective synthesis renders the new compound as an attractive candidate for advanced toxicological evaluation and a drug against hypertension.